ISO 13485 and GMP Certificate Validity Requirements in Jordan
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Jordan scrutinises the remaining validity of the quality management system certificate strictly at the formal review stage. The practical red line given by GRZAN is this: on the day the registration application is submitted through the electronic system, the remaining validity of the manufacturer’s ISO 13485 certificate or home-country GMP certificate must be no less than 6 months. Certificates whose remaining validity is too short are highly likely to be rejected outright at the formal review stage (practical estimate).
- Second conclusion: the rationale for the 6-month red line comes from Jordan’s review cycle itself. The practical cycle for device registration is 4 to 8 months (approximately 4 months for Class I and approximately 8 months for Class III); if only 2 to 3 months of validity remain at submission, the certificate will expire during the review.
- Third conclusion: a change notification must be filed after a certificate is renewed. Once the manufacturer’s ISO 13485, CE or FDA certificate is renewed or reissued, an updated copy should be provided to the JFDA through the AR, and the corresponding variation study fee is 25 JOD.
2. Legal basis
The requirements relating to quality management system certificates in Jordan rest on the instruments listed below. Each entry identifies the reference, the publication date and the location of the relevant provisions.
| Title of regulation | Reference number | Publication date | Provision / location |
| Medical Devices (Including Sterilizers and Disinfectants) Importation Directives | Medical Devices Importation Directives Including Sterilizers & Detergents | Currently effective version | Provisions on submission of the quality management system certificate |
| Good Manufacturing Practice Guidelines for Medical Devices | Good Manufacturing Practice Guidelines for Medical Devices | 2011 | Provisions on production quality management requirements |
| JFDA fee schedule | Official JFDA fee items | Currently effective version | Variation study 25 JOD; site approval 700 JOD |
Provision numbers are subject to the Arabic originals published in the Jordanian Official Gazette and issued by the JFDA; the amounts are the official fees listed in the JFDA fee schedule; the 6-month validity red line and the 4-to-8-month cycle are practical estimates.
3. Expert insights
The observations below reflect GRZAN’s review of certificate validity practices among manufacturers submitting registration applications to the JFDA electronic system.
Insight 1: the cost of rejection at formal review is seriously underestimated. A rejection at the formal review stage never enters technical review. In theory it is “only a resubmission”, but in practice it resets the queue position and may cause the company to miss the Cosmo appointment slot already secured by the AR, so the real loss is counted in weeks. GRZAN therefore treats the queue reset, not the resubmission itself, as the real cost of the shortfall.
Insight 2: the ISO 13485 certificate and the home-country GMP certificate stand in an “or” relationship. The company may submit either one of the two. For Chinese manufacturers, if they already hold a medical device production licence issued by the NMPA together with an ISO 13485 certificate, they will usually submit the ISO 13485 certificate first, because it carries higher international recognisability.
Insight 3: the content requirements of the GMP guidelines and ISO 13485 are not fully equivalent. ISO 13485 is a management system certification standard, whereas the 2011 GMP guidelines describe Jordan’s specific requirements for the manufacturing process (design and development, purchasing, production control, inspection and testing, control of nonconforming product, corrective and preventive action, and management review). Holding an ISO 13485 certificate does not automatically satisfy the technical descriptions in the GMP guidelines.
Insight 4: the completeness of the certificate chain is as important as its validity. Beyond the ISO 13485 and GMP certificates, the CE certificate, the FDA approval documents and the FSC all carry validity periods. Companies should maintain a unified certificate register that places every certificate on which valid Jordanian registration depends under an expiry alert.
Insight 5: site approval is another compliance line on the manufacturing side. The site approval fee in the JFDA fee schedule is 700 JOD. High-risk devices and first-time applicants face a comparatively higher probability of being required to undergo site approval, so companies should reserve budget for it.
4. Practical recommendations
- First, make the certificate validity check a mandatory gate before submission. Set up a checkpoint ahead of the submission date to verify that the remaining validity of the ISO 13485 and GMP certificates is no less than 6 months (practical estimate); where it falls short, arrange renewal first.
- Second, establish a certificate expiry register. Set expiry alerts for the five categories of certificate — ISO 13485, GMP, CE, FDA and FSC — and start renewal 12 months in advance.
- Third, file the change notification immediately after renewal is completed. Submit the updated copy to the JFDA through the AR; the variation study fee is 25 JOD.
- Fourth, run an internal system self-check along the seven elements of the GMP guidelines. Ensure that records for design and development, purchasing, production control, inspection and testing, control of nonconforming product, corrective and preventive action, and management review can be retrieved at any time.
5. Verification checklist
- □ On the submission day, the remaining validity of the ISO 13485 or home-country GMP certificate is no less than 6 months (practical estimate)
- □ The validity of the CE certificate, FDA approval documents and FSC has been checked against the review cycle
- □ An expiry register covering the five certificate categories is in place, with renewal started 12 months ahead
- □ After renewal, the updated copy has been submitted to the JFDA through the AR (variation study 25 JOD)
- □ The internal system self-check has been completed against the seven elements of the GMP guidelines
- □ A budget of 700 JOD has been reserved for site approval
- □ The cited provision numbers have been re-verified against the Arabic text of the Official Gazette
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team prepares JFDA-compliant dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us